Bilateral mammoplasty for cancer: Surgical, oncological and patient-reported outcomes

详细信息    查看全文

• 作者：R. Di Micco^a ; ^b ; R.L. O'Connell^a ; P.A. Barry^a ; N. Roche^c ; F.A. MacNeill^c ; J.E. Rusby^a ;
• 关键词：Therapeutic mammoplasty ; Breast cancer ; Bilateral breast reduction ; Clavien Dindo classification ; BREAST-Q
• 刊名：European Journal of Surgical Oncology (EJSO)
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：43
• 期：1
• 页码：68-75
• 全文大小：411 K
• 卷排序：43

文摘

Bilateral mammoplasty (BM) can optimise oncological safety and aesthetic outcomes in women with large or ptotic breasts whose tumour to breast volume ratio or tumour location pose a challenge to standard breast-conserving therapy (BCT) and for whom mastectomy (with or without reconstruction) may be the only alternative.MethodsWe undertook a comprehensive analysis of surgical outcomes (complications according to the Clavien Dindo classification), acute radiation morbidity (Radiation Therapy Oncology Group classification), oncological outcomes, and patient satisfaction (BREAST-Q questionnaire) in women who underwent BM for breast cancer (BC) from June 2009–November 2014.Results168 women were included. Median age was 55 years (range:33–84) and median tumour size at imaging 35 mm (range:0–170). Median specimen weight was 242 g (range 39–1824). The wise pattern technique was used in 87.5% of procedures. At least one complication occurred in 68 (40.5%) women, mostly Clavien Dindo grade 1. Grade 3 complications were infrequent (8.9%) but occurred mainly on the therapeutic mammoplasty (TM) side (p < 0.05). Complications were associated with higher BMI, specimen weight and longer time to radiotherapy (p < 0.05).Median follow-up was 37 months (range: 13–77). Local recurrence occurred in 3 (1.8%), distant metastases in 5 (3.0%), and 10 (6.0%) women have died. The median score for ‘satisfaction with breasts’ was 77 (range: 0–100).ConclusionsThis study provides concurrent data on surgical, oncological and patient-reported outcomes. It offers evidence that BM is an effective treatment for breast cancer in large- or ptotic-breasted women.